The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of gemcitabine, irinotecan, and panitumumab in advanced cholangiocarcinoma, with correlative analysis of EGFR, KRAS, and BRAF: An interim report.
Davendra Sohal
No relevant relationships to disclose
Ursina R. Teitelbaum
No relevant relationships to disclose
Takeshi Uehara
No relevant relationships to disclose
Kristine Mykulowycz
No relevant relationships to disclose
Christopher D. Watt
No relevant relationships to disclose
Nevena Damjanov
No relevant relationships to disclose
Bruce J. Giantonio
No relevant relationships to disclose
Mary Carberry
No relevant relationships to disclose
Paul Stephen Wissel
No relevant relationships to disclose
Mona Jacobs-Small
No relevant relationships to disclose
Peter J. O'Dwyer
No relevant relationships to disclose
Antonia Sepulveda
No relevant relationships to disclose
Weijing Sun
No relevant relationships to disclose